Cargando…

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex

Tuberous sclerosis complex (TSC), caused by loss-of-function mutations in the TSC1 or TSC2 genes, is an autosomal dominant disease characterized by benign tumor formation in multiple organs. Hyperactivation of mammalian target of rapamycin (mTOR) is the primary alteration underlying TSC tumor. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Shuang, Lin, Wei, Wang, Li, Ni, Zhaofei, Jin, Fuquan, Zha, Xiaojun, Fei, Guanghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370499/ https://www.ncbi.nlm.nih.gov/pubmed/28367235 http://dx.doi.org/10.7150/jca.17205

Ejemplares similares

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
por: Xiang, Ru-Fang, et al.
Publicado: (2017)

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro
por: Chen, Meiling, et al.
Publicado: (2022)

PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
por: Qi, Lei, et al.
Publicado: (2015)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

Erratum to: PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
por: Qi, Lei, et al.
Publicado: (2015)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development
por: Wang, Li, et al.
Publicado: (2017)

Raptor Preys on mTOR Imbalance in Tuberous Sclerosis
por: Ramamurthy, Aishwarya, et al.
Publicado: (2023)

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells
por: Malkomes, Patrizia, et al.
Publicado: (2016)

Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells
por: Djuzenova, Cholpon S., et al.
Publicado: (2019)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
por: Zhao, Yuan-Yuan, et al.
Publicado: (2014)

Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines
por: Dong, Yudi, et al.
Publicado: (2020)

Is mTOR inhibition a systemic treatment for tuberous sclerosis?
por: Moavero, Romina, et al.
Publicado: (2013)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
por: Brana, I, et al.
Publicado: (2014)

Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206
por: Rehan, Mohd, et al.
Publicado: (2014)

Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
por: Wilson, Jacob M, et al.
Publicado: (2015)

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
por: Pant, Alok, et al.
Publicado: (2012)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
por: Ahn, Daniel H., et al.
Publicado: (2015)

YAP enters the mTOR pathway to promote tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2015)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018)

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma
por: Al-Saffar, Nada M. S., et al.
Publicado: (2018)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)

The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures
por: Narayan, Ravi S., et al.
Publicado: (2017)

MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition
por: Sun, Dingqi, et al.
Publicado: (2020)

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
por: Gao, Hai-Ling, et al.
Publicado: (2023)

mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
por: Polchi, Alice, et al.
Publicado: (2018)

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
por: Agarwal, Ekta, et al.
Publicado: (2014)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation
por: Jin, Piaopiao, et al.
Publicado: (2016)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
por: Krummel, Thierry, et al.
Publicado: (2014)

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
por: Magri, Laura, et al.
Publicado: (2013)

The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
por: Goldstein, Hannah E., et al.
Publicado: (2021)

RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
por: Evans, Naomi, et al.
Publicado: (2020)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018)

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uuscfmd303oc5of6imqv22rapi